Citations

Clear

477 citation(s) found for "Wallace, AM".

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele, Angela, Yee, Douglas , Berry, Donald A. , Albain, Kathy S. , Benz, Christopher C. , Buxton, Meredith , Chia, Stephen , Chien, A. Jo , Clark, Amy S. , Edmiston, Kirsten K., Forero‐Torres, Andres , Haddad, Tufia C. , Haley, Barbara , Haluska, Paul , Korde, Larissa A. , Leyland‐Jones, Brian , Liu, Minetta C. , Melisko, Michelle , Minton, Susan, Moulder, Stacy L. , Nanda, Rita , Olopade, Olufunmilayo I. , Paoloni, Melissa, Park, John W., Parker, Barbara A. , Perlmutter, Jane , Petricoin, Emanuel F. , Symmans, Fraser, Tripathy, Debasish , Veer, Laura J. van’t , Viscusi, Rebecca K., Symmans, W. Fraser , Boughey, Judy, Boughey, Judy C. , Hui, Jane Yuet Ching , Elias, Anthony , Hylton, Nola M. , Isaacs, Claudine , Kaplan, Henry G. , Rugo, Hope S. , Wallace, Anne M. , Wolf, Denise M. , Yau, Christina , Esserman, Laura J. , Olopade, Olufunmilayo I , Symmans, W Fraser , Yee, Douglas

Mayo Clinic

Clinical Cancer Research | February 26, 2015 | Volume: 21 | Issue: 13 | Pages: 2911-2915

10.1158/1078-0432.ccr-14-1760 | PMID 25712686 Get It

AbstractThe many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach. Clin Cancer Res; 21(13); 2911–5. ©2015 AACR.
Diminutive colorectal polyp resection comparing hot and cold snare and cold biopsy forceps polypectomy. Results of a pilot randomized, single-center study
Gómez, Victoria , Badillo, Raul, Krishna, Murli, Diehl, Nancy N. , Badillo, Raul J, Crook, Julia E. , Wallace, Michael B.

Mayo Clinic

Endoscopy International Open | January 14, 2015 | Volume: 03 | Issue: 01 | Pages: C1-C1

10.1055/s-0034-1391366 | PMID 27547814 Get It

In‐vivo microscopy in the diagnosis of intestinal neoplasia and inflammatory conditions
Buchner, Anna M. , Wallace, Michael B. , Wallace, Michael B

Mayo Clinic

Histopathology | January 14, 2015 | Volume: 66 | Issue: 1 | Pages: 137-146

10.1111/his.12597 | PMID 25639481 Get It

Confocal laser endomicroscopy (CLE) is a rapidly emerging tool in endoscopic imaging allowing in‐vivo microscopy of examined gastrointestinal mucosa. This review will discuss the most recent advances of confocal laser endomicroscopy in the diagnosis of intestinal neoplasia and inflammatory conditions.
Preoperative endoscopic ultrasound-guided fine needle aspiration does not impair survival of patients with resected pancreatic cancer
Ngamruengphong, Saowanee , Swanson, Kristi M. , Shah, Nilay D. , Wallace, Michael B. , Wallace, Michael B

Mayo Clinic

Gut | January 10, 2015 | Volume: 64 | Issue: 7 | Pages: 1105-1110

10.1136/gutjnl-2014-307475 | PMID 25575893 Get It

Objective Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) allows preoperative tissue confirmation of malignancy, but fear of tumour cell dissemination along the needle track has limited its use. We hypothesised that if tumour cell dissemination occurs with EUS-FNA, survival after complete resection would be impaired. We aimed to evaluate the association of preoperative EUS-FNA with long-term outcomes of patients with resected pancreatic cancer. Design Using the linked Surveillance, Epidemiology, and End Results (SEER)–Medicare data, we identified patients with locoregional pancreatic cancer who underwent curative intent surgery from 1998 to 2009. The patients who received EUS-FNA within the peridiagnostic period were included in the EUS-FNA group. Patients who did not receive EUS evaluation or who underwent EUS without FNA were included in the non-EUS-FNA group. Overall survival and pancreatic cancer-specific survival were compared after controlling for relevant covariates. Results A total of 2034 patients with pancreatic cancer were included (90% pancreatic adenocarcinoma). Of these, 498 (24%) patients were in EUS-FNA group. Patients with multiple comorbidities and more recent diagnosis were more likely to receive EUS-FNA. In multivariate analysis, after controlling for age, race, gender, tumour histology, tumour stage, tumour grade, tumour location, SEER site, year of diagnosis, undergoing percutaneous aspiration/biopsy, Charlson Comorbidity Index, radiation and chemotherapy, EUS-FNA was marginally associated with improved overall survival (HR 0.84, 95% CI 0.72 to 0.99), but did not affect cancer-specific survival (HR 0.87, 95% CI 0.74 to 1.03). Conclusions Preoperative EUS-FNA was not associated with increased risk of mortality. These data suggest that EUS-FNA can be safely performed for the work-up of suspicious pancreatic lesions.
Diminutive colorectal polyp resection comparing hot and cold snare and cold biopsy forceps polypectomy. Results of a pilot randomized, single-center study (with videos)
Gómez, Victoria , Badillo, Raul, Crook, Julia, Krishna, Murli , Diehl, Nancy N. , Wallace, Michael B. , Badillo, Raul J, Crook, Julia E. , Wallace, Michael B

Mayo Clinic

Endoscopy International Open | November 20, 2014 | Volume: 03 | Issue: 01 | Pages: E76-E80

10.1055/s-0034-1390789 | PMID 26134778 Get It

Novel Method to Collect Medication Adverse Events in Juvenile Arthritis: Results From the Childhood Arthritis and Rheumatology Research Alliance Enhanced Drug Safety Surveillance Project
Ringold, Sarah , Hendrickson, Audrey, Abramson, Leslie, Beukelman, Timothy , Blier, Peter R., Bohnsack, John F. , Chalom, Elizabeth, Gewanter, Harry L., Gottlieb, Beth S. , Hollister, Roger, Hsu, Joyce , Hudgins, Andrea, Klein‐Gitelman, Marisa, Lindsley, Carol B., Lopez‐Benitez, Jorge M. , Lovell, Daniel J. , Mason, Tom, Milojevic, Diana , Moorthy, Lakshmi N., Nanda, Kabita , Onel, Karen , Rabinovich, C. Egla, Ray, Linda, Rouster‐Stevens, Kelly , Ruth, Natasha M. , Shishov, Michael , Spalding, Steven J., Syed, Reema , Vehe, Richard K. , Weiss, Jennifer E. , White, Andrew J. , Wallace, Carol A., Sobel, Rachel E. , Ilowite, Norman T. , Moorthy, L. Nandini , Prahalad, Sampath , Stoll, Matthew Laurence , White, Andrew J

Mayo Clinic

Arthritis Care & Research | October 20, 2014 | Volume: 67 | Issue: 4 | Pages: 529-537

10.1002/acr.22487 | PMID 25331530 Get It

ObjectiveFew data are available regarding the rates of serious adverse events (SAEs) and important medical events (IMEs) outside of product‐based registries and clinical trials for juvenile idiopathic arthritis (JIA). The Enhanced Drug Safety Surveillance Project (EDSSP) was developed to pilot a novel system to collect SAEs/IMEs in children with JIA. This analysis reports the results from this 4‐year (2008–2012) EDSSP.MethodsParticipating physicians were surveyed monthly to ascertain whether their JIA patients experienced an SAE or IME. Sites were surveyed every 6 months to determine the number of unique JIA patients seen at each site during that 6‐month period. Reporting rates were calculated per 100 person‐years and 95% confidence intervals (95% CIs) were calculated based on a Poisson distribution.ResultsThirty‐seven Childhood Arthritis and Rheumatology Research Alliance sites with 115 physicians participated. The mean response rate to the monthly surveys was 65%. There were 147 total SAEs and 145 total IMEs. The largest proportion of SAEs and IMEs occurred in children with polyarticular JIA (39% and 37%, respectively). The majority of SAEs and IMEs were reported for patients receiving therapy with biologic agents (76% and 69%, respectively). The total event rate for SAEs and IMEs combined was 1.07 events per 100 person‐years (95% CI 0.95–1.19). The rates for SAEs and IMEs were 0.54 per 100 person‐years (95% CI 0.45–0.63) and 0.53 per 100 person‐years (95% CI 0.49–0.62), respectively.ConclusionThe EDSSP provided a simple tool for SAE/IME reporting within an established research network and resulted in a similar range of reported events as captured by a traditional product‐based registry.
Tenosynovitis Caused by a Novel Nontuberculous Mycobacterium Species Initially Misidentified as a Member of the Mycobacterium tuberculosis Complex
Simner, Patricia J. , Hyle, Emily P. , Buckwalter, Seanne P., Branda, John A. , Brown‐Elliott, Barbara A. , Franklin, Jameelah Atiya, Toney, Nadege C. , Man, Tom J. B. de , Wallace, Richard J. , Vasireddy, Ravikiran, Gandhi, Rajesh T. , Wengenack, Nancy L.

Mayo Clinic

Journal of Clinical Microbiology | September 25, 2014 | Volume: 52 | Issue: 12 | Pages: 4414-4418

10.1128/jcm.00967-14 | PMID 25253791 Get It

ABSTRACT We present a case of tenosynovitis caused by a novel, slowly growing, nonchromogenic, nontuberculous mycobacterium (NTM). Originally misidentified as Mycobacterium tuberculosis complex, the NTM cross-reacts with the M. tuberculosis complex nucleic acid hybridization probe, a M. tuberculosis gamma interferon release assay, and is closely related to M. tuberculosis by 16S rRNA gene sequencing.
Optum Labs: Building A Novel Node In The Learning Health Care System
Wallace, Paul , Shah, Nilay D. , Dennen, Taylor, Bleicher, Paul A. , Crown, William H.

Mayo Clinic

Health Affairs | July 8, 2014 | Volume: 33 | Issue: 7 | Pages: 1187-1194

10.1377/hlthaff.2014.0038 | PMID 25006145 Get It

Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System
Crandall, Wallace, Joffe, Marshall M., Colletti, Richard B. , Adler, Jeremy, Baron, Howard, Berman, James , Rosario, J. Fernando del , Grossman, Andrew B., Israel, Esther J. , Kim, Sandra C. , Lightdale, Jenifer R. , Margolis, Peter A. , Marsolo, Keith , Mehta, Devendra I. , Milov, David E., Patel, Ashish , Tung, Jeanne , Forrest, Christopher B. , Bailey, L. Charles , Zhang, Peixin , Adler, Jeremy, Hoffenberg, Edward J. , Kappelman, Michael D. , Adler, J

Mayo Clinic

Pediatrics | June 17, 2014 | Volume: 134 | Issue: 1 | Pages: 37-44

10.1542/peds.2013-4103 | PMID 24935993 Get It

OBJECTIVES: ImproveCareNow (ICN) is the largest pediatric learning health system in the nation and started as a quality improvement collaborative. To test the feasibility and validity of using ICN data for clinical research, we evaluated the effectiveness of anti-tumor necrosis factor-α (anti-TNFα) agents in the management of pediatric Crohn disease (CD). METHODS: Data were collected in 35 pediatric gastroenterology practices (April 2007 to March 2012) and analyzed as a sequence of nonrandomized trials. Patients who had moderate to severe CD were classified as initiators or non-initiators of anti-TNFα therapy. Among 4130 patients who had pediatric CD, 603 were new users and 1211 were receiving anti-TNFα therapy on entry into ICN. RESULTS: During a 26-week follow-up period, rate ratios obtained from Cox proportional hazards models, adjusting for patient and disease characteristics and concurrent medications, were 1.53 (95% confidence interval [CI], 1.20–1.96) for clinical remission and 1.74 (95% CI, 1.33–2.29) for corticosteroid-free remission. The rate ratio for corticosteroid-free remission was comparable to the estimate produced by the adult SONIC study, which was a randomized controlled trial on the efficacy of anti-TNFα therapy. The number needed to treat was 5.2 (95% CI, 3.4–11.1) for clinical remission and 5.0 (95% CI, 3.4–10.0) for corticosteroid-free remission. CONCLUSIONS: In routine pediatric gastroenterology practice settings, anti-TNFα therapy was effective at achieving clinical and corticosteroid-free remission for patients who had Crohn disease. Using data from the ICN learning health system for the purpose of observational research is feasible and produces valuable new knowledge.